IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG

Melvin Berger, Thomas Harbo, David Cornblath, Orell Mielke

Research output: Contribution to journalArticle

Abstract

Subcutaneous IgG (SCIG) administration may be preferred over the intravenous route (IVIG) in chronic inflammatory demyelinating polyneuropathy (CIDP) because it minimizes 'end of cycle' treatment-related fluctuations, reduces systemic adverse effects, improves convenience/quality of life and potentially lowers overall costs. Early reports of the use of highly concentrated SCIG preparations suggested they were effective and well-tolerated in chronic inflammatory demyelinating polyneuropathy. This was confirmed in the Polyneuropathy and Treatment with Hizentra® study of 172 subjects randomized to receive maintenance therapy with placebo or one of two doses of IgPro20 (20% IgG stabilized with L-Proline) for 6 months. Risk of relapse was reduced by SCIG in a dose-related manner as compared with placebo. A total of 88% of polyneuropathy and treatment with hizentra subjects felt the subcutaneous method was 'easy to learn'. Local adverse events were mostly mild or moderate, and systemic adverse events were infrequent. Some patients may prefer maintenance therapy with SCIG over IVIG.

Original languageEnglish (US)
Pages (from-to)919-933
Number of pages15
JournalImmunotherapy
Volume10
Issue number11
DOIs
StatePublished - Aug 1 2018

Fingerprint

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Polyneuropathies
Immunoglobulin G
Intravenous Immunoglobulins
Placebos
Therapeutics
Proline
Quality of Life
Hizentra
Costs and Cost Analysis
Recurrence

Keywords

  • CIDP
  • IgG
  • IgPro20
  • intravenous IgG
  • IVIG
  • neuropathy
  • PATH study
  • SCIG
  • subcutaneous IgG

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG. / Berger, Melvin; Harbo, Thomas; Cornblath, David; Mielke, Orell.

In: Immunotherapy, Vol. 10, No. 11, 01.08.2018, p. 919-933.

Research output: Contribution to journalArticle

@article{3e276f5dd0b246c98a79e7cabb32412a,
title = "IgPro20, the Polyneuropathy and Treatment with Hizentra{\circledR} study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG",
abstract = "Subcutaneous IgG (SCIG) administration may be preferred over the intravenous route (IVIG) in chronic inflammatory demyelinating polyneuropathy (CIDP) because it minimizes 'end of cycle' treatment-related fluctuations, reduces systemic adverse effects, improves convenience/quality of life and potentially lowers overall costs. Early reports of the use of highly concentrated SCIG preparations suggested they were effective and well-tolerated in chronic inflammatory demyelinating polyneuropathy. This was confirmed in the Polyneuropathy and Treatment with Hizentra{\circledR} study of 172 subjects randomized to receive maintenance therapy with placebo or one of two doses of IgPro20 (20{\%} IgG stabilized with L-Proline) for 6 months. Risk of relapse was reduced by SCIG in a dose-related manner as compared with placebo. A total of 88{\%} of polyneuropathy and treatment with hizentra subjects felt the subcutaneous method was 'easy to learn'. Local adverse events were mostly mild or moderate, and systemic adverse events were infrequent. Some patients may prefer maintenance therapy with SCIG over IVIG.",
keywords = "CIDP, IgG, IgPro20, intravenous IgG, IVIG, neuropathy, PATH study, SCIG, subcutaneous IgG",
author = "Melvin Berger and Thomas Harbo and David Cornblath and Orell Mielke",
year = "2018",
month = "8",
day = "1",
doi = "10.2217/imt-2018-0036",
language = "English (US)",
volume = "10",
pages = "919--933",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "11",

}

TY - JOUR

T1 - IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG

AU - Berger, Melvin

AU - Harbo, Thomas

AU - Cornblath, David

AU - Mielke, Orell

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Subcutaneous IgG (SCIG) administration may be preferred over the intravenous route (IVIG) in chronic inflammatory demyelinating polyneuropathy (CIDP) because it minimizes 'end of cycle' treatment-related fluctuations, reduces systemic adverse effects, improves convenience/quality of life and potentially lowers overall costs. Early reports of the use of highly concentrated SCIG preparations suggested they were effective and well-tolerated in chronic inflammatory demyelinating polyneuropathy. This was confirmed in the Polyneuropathy and Treatment with Hizentra® study of 172 subjects randomized to receive maintenance therapy with placebo or one of two doses of IgPro20 (20% IgG stabilized with L-Proline) for 6 months. Risk of relapse was reduced by SCIG in a dose-related manner as compared with placebo. A total of 88% of polyneuropathy and treatment with hizentra subjects felt the subcutaneous method was 'easy to learn'. Local adverse events were mostly mild or moderate, and systemic adverse events were infrequent. Some patients may prefer maintenance therapy with SCIG over IVIG.

AB - Subcutaneous IgG (SCIG) administration may be preferred over the intravenous route (IVIG) in chronic inflammatory demyelinating polyneuropathy (CIDP) because it minimizes 'end of cycle' treatment-related fluctuations, reduces systemic adverse effects, improves convenience/quality of life and potentially lowers overall costs. Early reports of the use of highly concentrated SCIG preparations suggested they were effective and well-tolerated in chronic inflammatory demyelinating polyneuropathy. This was confirmed in the Polyneuropathy and Treatment with Hizentra® study of 172 subjects randomized to receive maintenance therapy with placebo or one of two doses of IgPro20 (20% IgG stabilized with L-Proline) for 6 months. Risk of relapse was reduced by SCIG in a dose-related manner as compared with placebo. A total of 88% of polyneuropathy and treatment with hizentra subjects felt the subcutaneous method was 'easy to learn'. Local adverse events were mostly mild or moderate, and systemic adverse events were infrequent. Some patients may prefer maintenance therapy with SCIG over IVIG.

KW - CIDP

KW - IgG

KW - IgPro20

KW - intravenous IgG

KW - IVIG

KW - neuropathy

KW - PATH study

KW - SCIG

KW - subcutaneous IgG

UR - http://www.scopus.com/inward/record.url?scp=85052607680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052607680&partnerID=8YFLogxK

U2 - 10.2217/imt-2018-0036

DO - 10.2217/imt-2018-0036

M3 - Article

VL - 10

SP - 919

EP - 933

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 11

ER -